ORIC Pharmaceuticals, Inc. (ORIC)
$4.4
Rating:
Recommendation:
-
| Symbol | ORIC |
|---|---|
| Price | $4.4 |
| Beta | 2.362 |
| Volume Avg. | 0.50M |
| Market Cap | 173.704M |
| Shares () | - |
| 52 Week Range | 2.62-26.7 |
| 1y Target Est | - |
| DCF Unlevered | ORIC DCF -> | |
|---|---|---|
| DCF Levered | ORIC LDCF -> | |
| ROE | -37.87% | Strong Sell |
| ROA | -37.04% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 8.69% | Neutral |
| P/E | - | |
| P/B | 0.69 | Buy |
Latest ORIC news
About
Download (Excel)ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.